XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-50.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XTLB vs SIGA
Revenue, margins, valuation, and 5-year total return — side by side.
SIGA
SIGA Technologies, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$339M
5Y Perf.-21.0%
XTLB vs SIGA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XTLB | SIGA |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $294K | $339M |
| Revenue (TTM) | $451K | $94M |
| Net Income (TTM) | $-1M | $-4.04T |
| Gross Margin | 26.4% | 61.8% |
| Operating Margin | -481.6% | 27.7% |
| Forward P/E | — | 2.8x |
| Total Debt | $138K | $595K |
| Cash & Equiv. | $371K | $155M |
XTLB vs SIGA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XTLB
SIGA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| XTL Biopharmaceutic… (XTLB) | 100 | 49.8 | -50.2% |
| SIGA Technologies, … (SIGA) | 100 | 79.0 | -21.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XTLB vs SIGA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SIGA leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
XTLB
XTL Biopharmaceuticals Ltd.
The Growth Play
XTLB is the clearest fit if your priority is growth exposure.
- EPS growth 45.5%
- -227.7% margin vs SIGA's -43K%
Best for: growth exposure
SIGA
SIGA Technologies, Inc.
The Income Pick
SIGA carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 4 yrs, beta 1.15, yield 12.7%
- 7.6% 10Y total return vs XTLB's -87.3%
- Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SIGA | -31.8% revenue growth vs XTLB's -173.2% |
| Quality / Margins | XTLB | -227.7% margin vs SIGA's -43K% |
| Stability / Safety | SIGA | Beta 1.15 vs XTLB's 1.71, lower leverage |
| Dividends | SIGA | 12.7% yield; 4-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | SIGA | +1.5% vs XTLB's -50.9% |
| Efficiency (ROA) | SIGA | -7.4% ROA vs XTLB's -17.7%, ROIC 33.7% vs -54.1% |
XTLB vs SIGA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
XTLB vs SIGA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSIGALAGGINGXTLB
XTLBXTL Biopharmaceutical…
1leads
SIGASIGA Technologies, In…
4leads
6 Total Categories
CATEGORYLEADERvs XTLBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SIGA3/4
Valuation MetricsMultiples, price ratios, and targets
XTLB3/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SIGA7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
SIGA5/6
Risk & VolatilityBeta, volatility, and downside exposure
SIGA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SIGA leads this category, winning 3 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
SIGA is the larger business by revenue, generating $94M annually — 207.9x XTLB's $451,000. XTLB is the more profitable business, keeping -2.3% of every revenue dollar as net income compared to SIGA's -43117.4%.
| Metric | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… |
|---|---|---|
| RevenueTrailing 12 months | $451,000 | $94M |
| EBITDAEarnings before interest/tax | -$1M | $26M |
| Net IncomeAfter-tax profit | -$1M | -$4.04T |
| Free Cash FlowCash after capex | $0 | $33M |
| Gross MarginGross profit ÷ Revenue | +26.4% | +61.8% |
| Operating MarginEBIT ÷ Revenue | -4.8% | +27.7% |
| Net MarginNet income ÷ Revenue | -2.3% | -43117.4% |
| FCF MarginFCF ÷ Revenue | -3.7% | +35.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -11.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +20.0% | — |
SIGA leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
XTLB leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… |
|---|---|---|
| Market CapShares × price | $293,767 | $339M |
| Enterprise ValueMkt cap + debt − cash | $60,767 | $185M |
| Trailing P/EPrice ÷ TTM EPS | -0.28x | 14.33x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 2.78x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.60x |
| Price / SalesMarket cap ÷ Revenue | 0.65x | 3.58x |
| Price / BookPrice ÷ Book value/share | 0.05x | 1.70x |
| Price / FCFMarket cap ÷ FCF | — | 6.96x |
XTLB leads this category, winning 3 of 3 comparable metrics.
Profitability & Efficiency
SIGA leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
SIGA delivers a -10.7% return on equity — every $100 of shareholder capital generates $-11 in annual profit, vs $-26 for XTLB. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to XTLB's 0.03x. On the Piotroski fundamental quality scale (0–9), SIGA scores 5/9 vs XTLB's 3/9, reflecting solid financial health.
| Metric | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… |
|---|---|---|
| ROE (TTM)Return on equity | -25.5% | -10.7% |
| ROA (TTM)Return on assets | -17.7% | -7.4% |
| ROICReturn on invested capital | -54.1% | +33.7% |
| ROCEReturn on capital employed | -50.7% | +11.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.03x | 0.00x |
| Net DebtTotal debt minus cash | -$233,000 | -$154M |
| Cash & Equiv.Liquid assets | $371,000 | $155M |
| Total DebtShort + long-term debt | $138,000 | $595,169 |
| Interest CoverageEBIT ÷ Interest expense | -13.31x | — |
SIGA leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
SIGA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SIGA five years ago would be worth $10,136 today (with dividends reinvested), compared to $1,963 for XTLB. Over the past 12 months, SIGA leads with a +1.5% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors SIGA at 6.9% vs XTLB's -18.4% — a key indicator of consistent wealth creation.
| Metric | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… |
|---|---|---|
| YTD ReturnYear-to-date | +11.3% | -15.0% |
| 1-Year ReturnPast 12 months | -50.9% | +1.5% |
| 3-Year ReturnCumulative with dividends | -45.7% | +22.2% |
| 5-Year ReturnCumulative with dividends | -80.4% | +1.4% |
| 10-Year ReturnCumulative with dividends | -87.3% | +764.0% |
| CAGR (3Y)Annualised 3-year return | -18.4% | +6.9% |
SIGA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
SIGA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SIGA is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than XTLB's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SIGA currently trades 49.2% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.71x | 1.15x |
| 52-Week HighHighest price in past year | $10.28 | $9.62 |
| 52-Week LowLowest price in past year | $1.05 | $4.29 |
| % of 52W HighCurrent price vs 52-week peak | +26.0% | +49.2% |
| RSI (14)Momentum oscillator 0–100 | 57.0 | 47.0 |
| Avg Volume (50D)Average daily shares traded | 2.4M | 688K |
SIGA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
SIGA is the only dividend payer here at 12.73% yield — a key consideration for income-focused portfolios.
| Metric | XTLBXTL Biopharmaceut… | SIGASIGA Technologies… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | 1 |
| Dividend YieldAnnual dividend ÷ price | — | +12.7% |
| Dividend StreakConsecutive years of raises | — | 4 |
| Dividend / ShareAnnual DPS | — | $0.60 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SIGA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XTLB leads in 1 (Valuation Metrics).
Best OverallSIGA Technologies, Inc. (SIGA)Leads 4 of 6 categories
Loading custom metrics...
XTLB vs SIGA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is XTLB or SIGA a better buy right now?
SIGA Technologies, Inc.
(SIGA) offers the better valuation at 14. 3x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XTLB or SIGA?
Over the past 5 years, SIGA Technologies, Inc.
(SIGA) delivered a total return of +1. 4%, compared to -80. 4% for XTL Biopharmaceuticals Ltd. (XTLB). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XTLB or SIGA?
By beta (market sensitivity over 5 years), SIGA Technologies, Inc.
(SIGA) is the lower-risk stock at 1. 15β versus XTL Biopharmaceuticals Ltd. 's 1. 71β — meaning XTLB is approximately 48% more volatile than SIGA relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 3% for XTL Biopharmaceuticals Ltd. — giving it more financial flexibility in a downturn.
04Which has better profit margins — XTLB or SIGA?
SIGA Technologies, Inc.
(SIGA) is the more profitable company, earning 24. 6% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SIGA leads at 25. 1% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — SIGA leads at 68. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — XTLB or SIGA?
In this comparison, SIGA (12.
7% yield) pays a dividend. XTLB does not pay a meaningful dividend and should not be held primarily for income.
06Is XTLB or SIGA better for a retirement portfolio?
For long-horizon retirement investors, SIGA Technologies, Inc.
(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, XTLB: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between XTLB and SIGA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: XTLB is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock. SIGA pays a dividend while XTLB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.